|
1
|
Wu Y, Chen J, Zhu R, Huang G, Zeng J, Yu H, He Z, Han C. Integrating TCGA and Single-Cell Sequencing Data for Hepatocellular Carcinoma: A Novel Glycosylation (GLY)/Tumor Microenvironment (TME) Classifier to Predict Prognosis and Immunotherapy Response. Metabolites 2024; 14:51. [PMID: 38248854 PMCID: PMC10818448 DOI: 10.3390/metabo14010051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/05/2024] [Accepted: 01/09/2024] [Indexed: 01/23/2024] Open
Abstract
The major liver cancer subtype is hepatocellular carcinoma (HCC). Studies have indicated that a better prognosis is related to the presence of tumor-infiltrating lymphocytes (TILs) in HCC. However, the molecular pathways that drive immune cell variation in the tumor microenvironment (TME) remain poorly understood. Glycosylation (GLY)-related genes have a vital function in the pathogenesis of numerous tumors, including HCC. This study aimed to develop a GLY/TME classifier based on glycosylation-related gene scores and tumor microenvironment scores to provide a novel prognostic model to improve the prediction of clinical outcomes. The reliability of the signatures was assessed using receiver operating characteristic (ROC) and survival analyses and was verified with external datasets. Furthermore, the correlation between glycosylation-related genes and other cells in the immune environment, the immune signature of the GLY/TME classifier, and the efficacy of immunotherapy were also investigated. The GLY score low/TME score high subgroup showed a favorable prognosis and therapeutic response based on significant differences in immune-related molecules and cancer cell signaling mechanisms. We evaluated the prognostic role of the GLY/TME classifier that demonstrated overall prognostic significance for prognosis and therapeutic response before treatment, which may provide new options for creating the best possible therapeutic approaches for patients.
Collapse
Affiliation(s)
- Yun Wu
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
| | - Jiaru Chen
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
- School of Pharmacy, Guangdong Medical University, Dongguan 523808, China
| | - Riting Zhu
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
- School of Pharmacy, Guangdong Medical University, Dongguan 523808, China
| | - Guoliang Huang
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
| | - Jincheng Zeng
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
- Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan 523808, China
| | - Hongbing Yu
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
| | - Zhiwei He
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
| | - Cuifang Han
- Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China; (Y.W.); (J.C.); (R.Z.); (G.H.); (J.Z.); (H.Y.)
| |
Collapse
|
|
2
|
de Morais JMB, Cruz EMS, Concato VM, de Souza MC, Santos YM, Quadreli DH, Inoue FSR, Ferreira FB, Fernandes GSA, Bidóia DL, Machado RRB, Chuffa LGA, Pavanelli WR, Seiva FRF. Unraveling the impact of melatonin treatment: Oxidative stress, metabolic responses, and morphological changes in HuH7.5 hepatocellular carcinoma cells. Pathol Res Pract 2024; 253:155056. [PMID: 38183817 DOI: 10.1016/j.prp.2023.155056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/18/2023] [Accepted: 12/19/2023] [Indexed: 01/08/2024]
Abstract
In addition to its highly aggressive nature and late diagnosis, hepatocellular carcinoma (HCC) does not respond effectively to available chemotherapeutic agents. The search is on for an ideal and effective compound with low cost and minimal side effects that can be used as an adjunct to chemotherapeutic regimens. One of the mechanisms involved in the pathology of HCC is the oxidative stress, which plays a critical role in tumor survival and dissemination. Our group has already demonstrated the antitumor potential of melatonin against HuH 7.5 cells. In the present study, we focused on the effects of melatonin on oxidative stress parameters and their consequences on cell metabolism. HuH 7.5 cells were treated with 2 and 4 mM of melatonin for 24 and 48 h. Oxidative stress biomarkers, antioxidant enzyme, mitochondrial membrane potential, formation of lipid bodies and autophagic vacuoles, cell cycle progression, cell death rate and ultrastructural cell alterations were evaluated. The treatment with melatonin increased oxidative stress biomarkers and reduced antioxidant enzyme activities of HuH 7.5 cells. Additionally, melatonin treatment damaged the mitochondrial membrane and increased lipid bodies and autophagic vacuole formation. Melatonin triggered cell cycle arrest and induced cell death by apoptosis. Our results indicate that the treatment of HuH 7.5 cells with melatonin impaired antioxidant defense systems, inhibited cell cycle progression, and caused metabolic stress, culminating in tumor cell death.
Collapse
Affiliation(s)
- Juliana M B de Morais
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Ellen M S Cruz
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Virgínia M Concato
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Milena C de Souza
- North of Paraná State University (UENP), Biological Science Center, Bandeirantes, PR, Brazil
| | - Yasmin M Santos
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Débora H Quadreli
- General Biology Department, Biological Sciences Center, State University of Londrina, Londrina (UEL), PR, Brazil
| | - Fabrício S R Inoue
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Francielle B Ferreira
- North of Paraná State University (UENP), Biological Science Center, Bandeirantes, PR, Brazil
| | - Glaura S A Fernandes
- General Biology Department, Biological Sciences Center, State University of Londrina, Londrina (UEL), PR, Brazil
| | | | | | - Luiz Gustavo A Chuffa
- Department of Structural and Functional Biology, São Paulo State University (UNESP), Institute of Bioscience, Botucatu, SP, Brazil
| | - Wander R Pavanelli
- Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina (UEL), PR, Brazil
| | - Fábio R F Seiva
- Department of Chemical and Biological Sciences, São Paulo State University (UNESP), Institute of Bioscience, Botucatu, SP, Brazil.
| |
Collapse
|